CN105828817B - 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物 - Google Patents

含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物 Download PDF

Info

Publication number
CN105828817B
CN105828817B CN201580003056.5A CN201580003056A CN105828817B CN 105828817 B CN105828817 B CN 105828817B CN 201580003056 A CN201580003056 A CN 201580003056A CN 105828817 B CN105828817 B CN 105828817B
Authority
CN
China
Prior art keywords
pharmaceutical composition
salt
emulsifier
pyridine
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580003056.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105828817A (zh
Inventor
远藤洋子
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to CN201910493497.8A priority Critical patent/CN110251516B/zh
Publication of CN105828817A publication Critical patent/CN105828817A/zh
Application granted granted Critical
Publication of CN105828817B publication Critical patent/CN105828817B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201580003056.5A 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物 Active CN105828817B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910493497.8A CN110251516B (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2014002809 2014-01-10
JP2014-002809 2014-01-10
PCT/JP2015/050333 WO2015105134A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910493497.8A Division CN110251516B (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Publications (2)

Publication Number Publication Date
CN105828817A CN105828817A (zh) 2016-08-03
CN105828817B true CN105828817B (zh) 2019-07-05

Family

ID=53523959

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910493497.8A Active CN110251516B (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物
CN201580003056.5A Active CN105828817B (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910493497.8A Active CN110251516B (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物

Country Status (19)

Country Link
US (3) US20160317512A1 (ru)
EP (2) EP3093021B1 (ru)
JP (5) JP6012775B2 (ru)
KR (5) KR102230683B1 (ru)
CN (2) CN110251516B (ru)
AU (1) AU2015205268B2 (ru)
BR (1) BR112016015911B1 (ru)
CA (1) CA2934612C (ru)
EA (1) EA031723B1 (ru)
ES (2) ES2874547T3 (ru)
GE (1) GEP20186916B (ru)
HK (1) HK1224191A1 (ru)
IL (1) IL246654B (ru)
MX (1) MX2016009058A (ru)
MY (1) MY166210A (ru)
PH (1) PH12016501327A1 (ru)
SG (1) SG11201605532YA (ru)
TW (1) TWI612960B (ru)
WO (1) WO2015105134A1 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6012775B2 (ja) * 2014-01-10 2016-10-25 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
MX2020003133A (es) * 2014-01-10 2021-08-23 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
KR101824829B1 (ko) 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제
EP3320904B1 (en) 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
JPWO2018230713A1 (ja) 2017-06-16 2020-04-16 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
KR102619458B1 (ko) 2017-06-16 2023-12-29 학교법인 도시샤 mTOR 인히비터를 포함하는, 눈의 증상, 장해 또는 질환을 치료 또는 예방하기 위한 의약 및 그 응용
JP7250685B2 (ja) * 2017-09-29 2023-04-03 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬
CN111491636A (zh) 2017-12-21 2020-08-04 参天制药株式会社 奥米帕格的组合
JP7346305B2 (ja) * 2017-12-28 2023-09-19 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬製剤
JP7217364B2 (ja) * 2019-11-29 2023-02-02 千寿製薬株式会社 医薬組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
CN101970410A (zh) * 2008-03-12 2011-02-09 宇部兴产株式会社 吡啶基氨基乙酸化合物
CN102448940A (zh) * 2009-03-30 2012-05-09 宇部兴产株式会社 用于青光眼的治疗或预防的医药组合物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
JP3297969B2 (ja) * 1994-12-26 2002-07-02 ライオン株式会社 点眼剤
KR20010021835A (ko) * 1998-07-14 2001-03-15 제임스 에이. 아노 프로스타글란딘 생성물
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US20020009507A1 (en) * 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120058983A1 (en) * 2010-09-02 2012-03-08 Bayer Pharma Aktiengesellschaft Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
WO2014010654A2 (ja) * 2012-07-13 2014-01-16 参天製薬株式会社 スルホンアミド化合物の組み合わせ
US9339496B2 (en) * 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
US20140018350A1 (en) * 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
MX2020003133A (es) * 2014-01-10 2021-08-23 Santen Pharmaceutical Co Ltd Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
JP6012775B2 (ja) * 2014-01-10 2016-10-25 参天製薬株式会社 ピリジルアミノ酢酸化合物とポリオキシエチレンヒマシ油含有医薬組成物
KR101824829B1 (ko) * 2014-01-10 2018-02-01 산텐 세이야꾸 가부시키가이샤 피리딜아미노아세트산 화합물을 포함하는 의약 제제

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960799A (en) * 1988-09-13 1990-10-02 Ciba-Geigy Corporation Stabilized aqueous solutions of pharmaceutically acceptable salts of ortho-(2,6-dichlorophenyl)-aminophenylacetic acid for opthalmic use
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
CN101970410A (zh) * 2008-03-12 2011-02-09 宇部兴产株式会社 吡啶基氨基乙酸化合物
CN102448940A (zh) * 2009-03-30 2012-05-09 宇部兴产株式会社 用于青光眼的治疗或预防的医药组合物

Also Published As

Publication number Publication date
JP6449205B2 (ja) 2019-01-09
BR112016015911A2 (ru) 2017-08-08
BR112016015911B1 (pt) 2022-04-05
US20160317512A1 (en) 2016-11-03
KR101858373B1 (ko) 2018-05-15
AU2015205268B2 (en) 2019-03-14
JP2022189964A (ja) 2022-12-22
JP6012775B2 (ja) 2016-10-25
NZ721530A (en) 2021-03-26
PH12016501327B1 (en) 2017-02-06
EP3888654B1 (en) 2023-06-14
KR20160100977A (ko) 2016-08-24
ES2953346T3 (es) 2023-11-10
EP3093021B1 (en) 2021-06-02
EA031723B1 (ru) 2019-02-28
TWI612960B (zh) 2018-02-01
KR102230683B1 (ko) 2021-03-19
EP3888654A1 (en) 2021-10-06
WO2015105134A1 (ja) 2015-07-16
CA2934612A1 (en) 2015-07-16
KR20200053651A (ko) 2020-05-18
EP3093021A1 (en) 2016-11-16
KR20210032547A (ko) 2021-03-24
MY166210A (en) 2018-06-22
HK1224191A1 (zh) 2017-08-18
JP2017031177A (ja) 2017-02-09
GEP20186916B (en) 2018-11-12
EA201691139A1 (ru) 2017-02-28
CN110251516B (zh) 2022-05-03
JP2019034973A (ja) 2019-03-07
CN105828817A (zh) 2016-08-03
IL246654B (en) 2020-05-31
JP6793172B2 (ja) 2020-12-02
EP3093021A4 (en) 2017-07-26
MX2016009058A (es) 2016-09-09
KR20220146691A (ko) 2022-11-01
KR102458180B1 (ko) 2022-10-21
CN110251516A (zh) 2019-09-20
KR20180050770A (ko) 2018-05-15
AU2015205268A1 (en) 2016-07-14
PH12016501327A1 (en) 2017-02-06
JP7170020B2 (ja) 2022-11-11
CA2934612C (en) 2021-09-07
TW201611833A (en) 2016-04-01
US20200113880A1 (en) 2020-04-16
US20230372316A1 (en) 2023-11-23
KR102111157B1 (ko) 2020-05-14
SG11201605532YA (en) 2016-08-30
ES2874547T3 (es) 2021-11-05
IL246654A0 (en) 2016-08-31
JP2015147762A (ja) 2015-08-20
JP2021011508A (ja) 2021-02-04

Similar Documents

Publication Publication Date Title
CN105828817B (zh) 含有吡啶基氨基乙酸化合物和聚氧乙烯蓖麻油的药物组合物
CN108743587B (zh) 含有吡啶基氨基乙酸化合物的药物制剂
TWI650127B (zh) 含吡啶基胺基乙酸化合物之醫藥組成物
TW201705958A (zh) 含有吡啶基胺基乙酸化合物之預防及／或治療劑
JP2009040727A (ja) ラタノプロストを有効成分とする安定な点眼液剤
NZ721530B2 (en) Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1224191

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant